Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker
Ontology highlight
ABSTRACT: Interventions: Oral administration of pioglitazone in 15mg daily.
No administration of newly drug.
Primary outcome(s): Observation of ACF using magnifying endoscopy
Study Design: Parallel Randomized
DISEASE(S): Subjects With Aberrant Crypt Foci (acf)
PROVIDER: 2616758 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA